Document Type: Original Research

Authors

1 PhD, MD, Department of Medical Physics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

2 PhD, Associate Professor, Department of Medical Physics, Tarbiat Modares University, Tehran, Iran

3 PhD, Assistant Professor, Nuclear Science and Technology Research Institute, Tehran, Iran

4 MD, Associate Professor, Department of Radiation Oncology, Firouzgar Hospital, Iran University of Medical Sciences, Tehran, Iran

Abstract

Background: Cytogenetic tests are usually used for diagnosing predisposed individuals to cancer by determining their lymphocyte radiosensitivity.
Objective: To determine the potential role of radiosensitivity in predisposition of prostate cancer by comparing lymphocyte radiosensitivity of prostate cancer patients with healthy donors.
Materials and Methods: In this experimental study, the blood samples of 10 prostate cancer patients and 10 healthy donors were irradiated to 0.25, 0.5, 1, 2, 4 and 6 Gy ionizing radiation produced by a 6MV Linac. One sample of each group receiving no radiation was regarded as the background. The micronuclei (MN) and chemical premature chromosome condensation (PCC) cytogenetic tests were performed on all samples and the numbers of MN and PCC rings were scored. Dose-response curves were plotted for both healthy and cancerous groups with two tests.
Results: There was a significant difference between the numbers of MN within each group due to different levels of radiation doses. There was also a significant difference between the two groups in all identical doses, with the exception of 6 Gy. The chemical PCC test indicated a significant difference between the scored PCC rings in each group at doses higher than 0.25 Gy. However, no differences were noted between the healthy donors and prostate cancer patients receiving the same level of doses.
Conclusion: MN test can be considered as a reliable indicator of predisposition of prostate cancer. On the other hand, the chemical PCC test could not differentiate between healthy donors and prostate cancer patients at the dose range examined in this study.

Keywords

  1. Jackson SP. Sensing and repairing DNA double-strand breaks. Carcinogenesis. 2002;23:687-96. doi: 10.1093/carcin/23.5.687. PubMed PMID: 12016139.
  2. Matsuura S, Royba E, Akutsu SN, et al. Analysis of individual differences in radiosensitivity using genome editing. Ann ICRP. 2016;45:290-6. doi: 10.1177/0146645316633941. PubMed PMID: 27012844.
  3. Baria K, Warren C, Roberts SA, West CM, Scott D. Chromosomal radiosensitivity as a marker of predisposition to common cancers? Br J Cancer. 2001;84:892-6. doi: 10.1054/bjoc.2000.1701. PubMed PMID: 11286467. PubMed PMCID: 2363837.
  4. Ward JF. The complexity of DNA damage: relevance to biological consequences. Int J Radiat Biol. 1994;66:427-32. doi: 10.1080/09553009414551401. PubMed PMID: 7983426.
  5. Meschini R, Morucci E, Berni A, Lopez-Martinez W, Palitti F. Role of chromatin structure modulation by the histone deacetylase inhibitor trichostatin A on the radio-sensitivity of ataxia telangiectasia. Mutat Res. 2015;777:52-9. doi: 10.1016/j.mrfmmm.2015.04.009. PubMed PMID: 25942615.
  6. B Baeyens A, Thierens H, Claes K, Poppe B, et al. Chromosomal radiosensitivity in breast cancer patients with a known or putative genetic predisposition. Br J Cancer. 2002;87:1379-85. doi: 10.1038/sj.bjc.6600628. PubMed PMID: 12454765. PubMed PMCID: 2376291.
  7. Bonassi S, Hagmar L, Stromberg U, et al. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health. Cancer Res. 2000;60:1619-25. PubMed PMID: 10749131.
  8. Hagmar L, Brogger A, Hansteen IL, Heim S, et al. Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res. 1994;54:2919-22. PubMed PMID: 8187078.
  9. Bonassi S, Abbondandolo A, Camurri L, et al. Are chromosome aberrations in circulating lymphocytes predictive of future cancer onset in humans? Preliminary results of an Italian cohort study. Cancer Genet Cytogenet. 1995;79:133-5. doi: 10.1016/0165-4608(94)00131-T. PubMed PMID: 7889505.
  10. Hagmar L, Bonassi S, Stromberg U, et al. Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). Cancer Res. 1998;58:4117-21. PubMed PMID: 9751622.
  11. Bonassi S, Norppa H, Ceppi M, et al. Chromosomal aberration frequency in lymphocytes predicts the risk of cancer: results from a pooled cohort study of 22 358 subjects in 11 countries. Carcinogenesis. 2008;29:1178-83. doi: 10.1093/carcin/bgn075. PubMed PMID: 18356148. PubMed PMCID: 2443275.
  12. Scott D. Chromosomal radiosensitivity and low penetrance predisposition to cancer. Cytogenet Genome Res. 2004;104:365-70. doi: 10.1159/000077517. PubMed PMID: 15162066.
  13. Borgmann K, Raabe A, Reuther S, Szymczak S, et al. The potential role of G2- but not of G0-radiosensitivity for predisposition of prostate cancer. Radiother Oncol. 2010;96:19-24. doi: 10.1016/j.radonc.2010.04.018. PubMed PMID: 20452694.
  14. Scott D, Spreadborough A, Levine E, Roberts SA. Genetic predisposition in breast cancer. Lancet. 1994;344:1444. doi: 10.1016/S0140-6736(94)90615-7. PubMed PMID: 7968110.
  15. Slonina D, Gasinska A. Intrinsic radiosensitivity of healthy donors and cancer patients as determined by the lymphocyte micronucleus assay. Int J Radiat Biol. 1997;72:693-701. doi: 10.1080/095530097142852. PubMed PMID: 9416792.
  16. Scott D, Barber JB, Levine EL, Burrill W, Roberts SA. Radiation-induced micronucleus induction in lymphocytes identifies a high frequency of radiosensitive cases among breast cancer patients: a test for predisposition? Br J Cancer. 1998;77:614-20. doi: 10.1038/bjc.1998.98. PubMed PMID: 9484819. PubMed PMCID: 2149942.
  17. Rothfuss A, Schutz P, Bochum S, Volm T, et al. Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res. 2000;60:390-4. PubMed PMID: 10667592.
  18. Jagetia GC, Jayakrishnan A, Fernandes D, Vidyasagar MS. Evaluation of micronuclei frequency in the cultured peripheral blood lymphocytes of cancer patients before and after radiation treatment. Mutat Res. 2001;491:9-16. doi: 10.1016/S1383-5718(00)00132-7. PubMed PMID: 11287292.
  19. Baria K, Warren C, Eden OB, et al. Chromosomal radiosensitivity in young cancer patients: possible evidence of genetic predisposition. Int J Radiat Biol. 2002;78:341-6. doi: 10.1080/09553000110117359. PubMed PMID: 12020425.
  20. Mozdarani H, Mansouri Z, Haeri SA. Cytogenetic radiosensitivity of g0-lymphocytes of breast and esophageal cancer patients as determined by micronucleus assay. J Radiat Res. 2005;46:111-6. doi: 10.1269/jrr.46.111. PubMed PMID: 15802866.
  21. Varga D, Hoegel J, Maier C, Jainta S, et al. On the difference of micronucleus frequencies in peripheral blood lymphocytes between breast cancer patients and controls. Mutagenesis. 2006;21:313-20. doi: 10.1093/mutage/gel035. PubMed PMID: 16928695.
  22. Lisowska H, Lankoff A, Wieczorek A, et al. Enhanced chromosomal radiosensitivity in peripheral blood lymphocytes of larynx cancer patients. Int J Radiat Oncol Biol Phys. 2006;66:1245-52. doi: 10.1016/j.ijrobp.2006.07.1370. PubMed PMID: 17145539.
  23. Distel LV, Neubauer S, Keller U, et al. Individual differences in chromosomal aberrations after in vitro irradiation of cells from healthy individuals, cancer and cancer susceptibility syndrome patients. Radiother Oncol. 2006;81:257-63. doi: 10.1016/j.radonc.2006.10.012. PubMed PMID: 17113667.
  24. Shahidi M, Mozdarani H, Bryant PE. Radiation sensitivity of leukocytes from healthy individuals and breast cancer patients as measured by the alkaline and neutral comet assay. Cancer Lett. 2007;257:263-73. doi: 10.1016/j.canlet.2007.08.002. PubMed PMID: 17881118.
  25. Pantelias GE, Terzoudi GI. A standardized G2-assay for the prediction of individual radiosensitivity. Radiother Oncol. 2011;101:28-34. doi: 10.1016/j.radonc.2011.09.021. PubMed PMID: 22014898.
  26. Ryabchenko NM, Glavin OA, Shtefura VV, Anikushko MF. Chromosomal radiosensitivity in Ukrainian breast cancer patients and healthy individuals. Exp Oncol. 2012;34:121-4. PubMed PMID: 23013765.
  27. Encheva E, Deleva S, Hristova R, Hadjidekova V, Hadjieva T. Investigating micronucleus assay applicability for prediction of normal tissue intrinsic radiosensitivity in gynecological cancer patients. Rep Pract Oncol Radiother. 2011;17:24-31. doi: 10.1016/j.rpor.2011.10.002. PubMed PMID: 24376993. PubMed PMCID: 3863151.
  28. Farhan F, Azimi C, Mahmoodi M, Mohagheghi M-A, Farzanfar F, Noor-Mohammadi A, et al. Chromosomal radiosensitivity in lymphocytes of head and neck cancer patients as determind by mironucleus and G2 assays. Tehran University Medical Journal TUMS Publications. 2016;74:36-41.
  29. Scott D, Barber JB, Spreadborough AR, Burrill W, Roberts SA. Increased chromosomal radiosensitivity in breast cancer patients: a comparison of two assays. Int J Radiat Biol. 1999;75:1-10. doi: 10.1080/095530099140744. PubMed PMID: 9972785.
  30. Fenech M. Cytokinesis-block micronucleus cytome assay. Nat Protoc. 2007;2:1084-104. doi: 10.1038/nprot.2007.77. PubMed PMID: 17546000.
  31. Pajic J, Rakic B, Jovicic D, Milovanovic A. Construction of dose response calibration curves for dicentrics and micronuclei for X radiation in a Serbian population. Mutat Res Genet Toxicol Environ Mutagen. 2014;773:23-8. doi: 10.1016/j.mrgentox.2014.07.009. PubMed PMID: 25308702.
  32. WHO. Cytogenetic dosimetry: applications in preparedness for and response to radiation emergencies. Vienna: International Atomic Energy Agency; 2011.
  33. Pejchal J, Vasilieva V, Hristozova M, Vilasová Z, Vávrová J, Alyakov M, et al. Cytokinesis-block micronucleus (CBMN) assay/CBMN cytome assay in human lymphocytes after in vitro irradiation and its use in biodosimetry. Mil Med Sci Lett. 2011;80:28-37. doi: 10.31482/mmsl.2011.004.
  34. Rastkhah E, Zakeri F, Ghoranneviss M, et al. The cytokinesis-blocked micronucleus assay: dose-response calibration curve, background frequency in the population and dose estimation. Radiat Environ Biophys. 2016;55:41-51. doi: 10.1007/s00411-015-0624-3. PubMed PMID: 26507139.
  35. Sommer S, Buraczewska I, Sikorska K, et al. The rapid interphase chromosome assay (RICA) implementation: comparison with other PCC methods. Nukleonika. 2015;60:933-41. doi: 10.1515/nuka-2015-0147.
  36. Durante Y, Furusawa E, Gotoh M. Technical Report A simple method for simultaneous interphase-metaphase chromosome analysis in biodosimetry. International journal of radiation biology. 1998;74:457-62. doi: 10.1080/095530098141320.
  37. Karachristou I, Karakosta M, Pantelias A, et al. Triage biodosimetry using centromeric/telomeric PNA probes and Giemsa staining to score dicentrics or excess fragments in non-stimulated lymphocyte prematurely condensed chromosomes. Mutat Res Genet Toxicol Environ Mutagen. 2015;793:107-14. doi: 10.1016/j.mrgentox.2015.06.013. PubMed PMID: 26520380.
  38. Suto Y, Gotoh T, Noda T, Akiyama M, Owaki M, Darroudi F, et al. Assessing the applicability of FISH-based prematurely condensed dicentric chromosome assay in triage biodosimetry. Health Phys. 2015;108:371-6. doi: 10.1097/HP.0000000000000182. PubMed PMID: 25627950.
  39. M’Kacher R, El Maalouf E, Terzoudi G, et al. Detection and automated scoring of dicentric chromosomes in nonstimulated lymphocyte prematurely condensed chromosomes after telomere and centromere staining. Int J Radiat Oncol Biol Phys. 2015;91:640-9. doi: 10.1016/j.ijrobp.2014.10.048. PubMed PMID: 25596111.
  40. Hatzi VI, Terzoudi GI, Paraskevopoulou C, et al. The use of premature chromosome condensation to study in interphase cells the influence of environmental factors on human genetic material. Scientific World Journal. 2006;6:1174-90. doi: 10.1100/tsw.2006.210. PubMed PMID: 17013523.
  41. Lindholm C, Stricklin D, Jaworska A, et al. Premature chromosome condensation (PCC) assay for dose assessment in mass casualty accidents. Radiat Res. 2010;173:71-8. doi: 10.1667/RR1843.1. PubMed PMID: 20041761.